Colorectal cancer (CRC) is one of the most prevalent cancers, with more than one million
new cases every year. In the last few decades, several advancements in therapeutic and …

Introduction The traditional staging system is inadequate to identify those patients with stage
II colorectal cancer (CRC) at high risk of recurrence or with stage III CRC at low risk. A …

Background Identification of biomarkers associated with the prognosis of different cancer
subtypes is critical to achieve better therapeutic assistance. In colorectal cancer (CRC) the …

Colorectal cancer (CRC) is a major cause of global cancer mortality. Gene expression
profiles can help predict prognosis of patients with CRC. In most of previous studies, disease …

Current staging systems of cancer are mainly based on the anatomical extent of disease.
They need refinement by biological parameters to improve stratification of patients for tumor …

Colorectal cancer (CRC) is a leading cause of death among cancer patients. This
heterogeneous disease is characterized by alterations in multiple molecular pathways …

Colorectal cancer (CRC) has a complex pathogenesis involving multiple sequential steps
with accumulation of genetic alterations including mutations, gene amplification, and …

The current management of colorectal cancer (CRC) would greatly benefit from non‐
invasive prognostic biomarkers indicative of clinicopathological tumor characteristics. Here …

Aims Despite continual efforts to develop prognostic and predictive models of colorectal
cancer by using clinicopathological and genetic parameters, a clinical test that can …

Over the past two decades, several protein and genomic markers have refined the
prognostic information of colorectal cancer (CRC) and helped to predict which patient group …